Purpose: To identify possible factors that influence sexual function in men undergoing maximal androgen deprivation therapy (ADT). Patients and Methods: A descriptive exploration was performed looking at characteristi...Purpose: To identify possible factors that influence sexual function in men undergoing maximal androgen deprivation therapy (ADT). Patients and Methods: A descriptive exploration was performed looking at characteristics of twenty-two men reporting sexual activity after nine months of maximal ADT. This previously published Phase II study, involved 250 prostate cancer patients undergoing intermittent ADT. An analysis between this cohort and the group that did not maintain sexual function was performed to ascertain if age, testosterone level, functional status or maintenance of quadriceps strength had an impact upon sexual function. Results: There was no difference in age, testosterone level or ECOG performance status between the sexually active and non-sexually active groups. Over the course of 9 months of ADT, the sexually active group appeared to maintain quadriceps muscle strength as measured with physical stands, and maintained overall health as measured by quality of life questionaries, compared to the non-sexually active group. Conclusions: This retrospective study suggests that exercise during ADT may reduce the impact of ADT on sexual function. This warrants further testing, and could be the focus of future randomised controlled trials.展开更多
Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoi...Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoint inhibitors(ICI),have been therapeutically transformative in many tumour types,including gynaecological malignancies such as cervical and endometrial cancer.Unfortunately,these therapeutic successes have not been mirrored in ovarian cancer clinical studies.This review provides an overview of the ovarian tumour microenvironment(TME),particularly factors associated with survival,and explores current research into immunotherapeutic strategies in EOC,with an exploratory focus on novel therapeutics in navigating drug resistance.展开更多
文摘Purpose: To identify possible factors that influence sexual function in men undergoing maximal androgen deprivation therapy (ADT). Patients and Methods: A descriptive exploration was performed looking at characteristics of twenty-two men reporting sexual activity after nine months of maximal ADT. This previously published Phase II study, involved 250 prostate cancer patients undergoing intermittent ADT. An analysis between this cohort and the group that did not maintain sexual function was performed to ascertain if age, testosterone level, functional status or maintenance of quadriceps strength had an impact upon sexual function. Results: There was no difference in age, testosterone level or ECOG performance status between the sexually active and non-sexually active groups. Over the course of 9 months of ADT, the sexually active group appeared to maintain quadriceps muscle strength as measured with physical stands, and maintained overall health as measured by quality of life questionaries, compared to the non-sexually active group. Conclusions: This retrospective study suggests that exercise during ADT may reduce the impact of ADT on sexual function. This warrants further testing, and could be the focus of future randomised controlled trials.
基金LK has been supported by postgraduate scholarships from the Australian Government(National Health and Medical Research Council,2022/2021964)Sydney Cancer Partners(Cancer Institute New South Wales,2021/CBG0002).
文摘Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy,and despite advancements in therapeutics,most women unfortunately still succumb to their disease.Immunotherapies,in particular immune checkpoint inhibitors(ICI),have been therapeutically transformative in many tumour types,including gynaecological malignancies such as cervical and endometrial cancer.Unfortunately,these therapeutic successes have not been mirrored in ovarian cancer clinical studies.This review provides an overview of the ovarian tumour microenvironment(TME),particularly factors associated with survival,and explores current research into immunotherapeutic strategies in EOC,with an exploratory focus on novel therapeutics in navigating drug resistance.
